Abstract #1155

A Feasibility Study of Radiation Therapy Dose Escalation Guided by Spectroscopic Magnetic Resonance Imaging in Patients with Glioblastoma

Saumya S. Gurbani^1,2, Eric Mellon³, Brent D. Weinberg², Eduard Schreibmann¹, Andrew A. Maudlsey⁴, Sulaiman Sheriff⁴, Peter B. Barker⁵, Lawrence Kleinberg⁶, Lee A. D. Cooper⁷, Hui-Kuo Shu¹, and Hyunsuk Shim^1,2

¹Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, United States, ²Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, United States, ³Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL, United States, ⁴Department of Radiology, University of Miami Miller School of Medicine, Miami, FL, United States, ⁵Department of Radiology and Radiological Science, The Johns Hopkins University, Baltimore, MD, United States, ⁶Department of Radiation Oncology, The Johns Hopkins University, Baltimore, MD, United States, ⁷Department of Biomedical Informatics, Emory University School of Medicine, Atlanta, GA, United States

Glioblastoma (GBM) is a grade IV primary brain tumor with poor outcomes despite surgical resection, chemotherapy, and radiation. Often, disease will recur in regions in the penumbra of the treatment volume, hypothesized to occur because anatomic MRI does not fully capture neoplastic infiltration. Spectroscopic magnetic resonance imaging (sMRI) enables in vivo whole-brain analysis of metabolic activity, and has been shown to sensitively and specifically identify regions of non-enhancing, infiltrating tumor. We present an ongoing prospective clinical study to target metabolically active tumor identified by sMRI for a radiation boost, with the aim of improving outcome in patients with GBM.

This abstract and the presentation materials are available to members only; a login is required.

Join Here